INZY - Inozyme Pharma, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Boston,
United States
Type: Equity
INZY price evolution
INZY
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $15.54 | $20.93 | $34.9 | |
| Short term investments | $129.29 | $145.53 | $154 | |
| Net receivables | $0.39 | |||
| Inventory | ||||
| Total current assets | $140.94 | $152.96 | $174.32 | $196.25 |
| Long term investments | ||||
| Property, plant & equipment | $1.66 | $1.98 | $2.31 | $2.59 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $2.75 | $2.62 | $4.6 | |
| Total investments | $129.29 | $145.53 | $154 | |
| Total assets | $143.36 | $155.71 | $176.94 | $200.85 |
| Current liabilities | ||||
| Accounts payable | $2.21 | $3.53 | $2.17 | $1.17 |
| Deferred revenue | ||||
| Short long term debt | $0.96 | $0.93 | $0.91 | |
| Total current liabilities | $18.34 | $15.54 | $12.41 | $14.69 |
| Long term debt | $42.06 | $45.75 | $45.7 | $45.68 |
| Total noncurrent liabilities | $45.75 | $45.7 | $45.68 | |
| Total debt | $46.71 | $46.63 | $46.59 | |
| Total liabilities | $60.57 | $61.29 | $58.11 | $60.37 |
| Shareholders' equity | ||||
| Retained earnings | -$360.88 | -$336.31 | -$309.28 | -$285.93 |
| Other shareholder equity | $0.19 | -$0.1 | -$0.1 | $0.04 |
| Total shareholder equity | $94.42 | $118.84 | $140.48 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $34.9 | $32.91 | $23.67 | $28.39 |
| Short term investments | $154 | $94.95 | $88.48 | $119.66 |
| Net receivables | $0.39 | $0.12 | $0.06 | $0.2 |
| Inventory | ||||
| Total current assets | $196.25 | $131.39 | $115.34 | $150.98 |
| Long term investments | $12.2 | |||
| Property, plant & equipment | $2.59 | $3.64 | $4.44 | $2.65 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $4.6 | $7.8 | $8.2 | $18.38 |
| Total investments | $154 | $94.95 | $88.48 | $131.86 |
| Total assets | $200.85 | $139.19 | $123.54 | $169.36 |
| Current liabilities | ||||
| Accounts payable | $1.17 | $2.54 | $2.39 | $3.07 |
| Deferred revenue | ||||
| Short long term debt | $0.91 | $0.82 | $0.73 | |
| Total current liabilities | $14.69 | $14.71 | $11.63 | $9.97 |
| Long term debt | $45.68 | $4.14 | $2.64 | $1.29 |
| Total noncurrent liabilities | $45.68 | $6.09 | $2.64 | $1.29 |
| Total debt | $46.59 | $6.78 | $3.37 | $1.29 |
| Total liabilities | $60.37 | $20.8 | $14.27 | $11.26 |
| Shareholders' equity | ||||
| Retained earnings | -$285.93 | -$214.76 | -$147.7 | -$91.08 |
| Other shareholder equity | $0.04 | -$0.2 | $0.02 | $0 |
| Total shareholder equity | $140.48 | $118.39 | $109.27 | $158.1 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $21.76 | $19.11 | $17.98 | |
| Selling, general & administrative | $5.91 | $5.23 | $4.83 | |
| Total operating expenses | $24.85 | $27.66 | $24.34 | $22.81 |
| Operating income | -$27.66 | -$24.34 | -$22.81 | |
| Income from continuing operations | ||||
| EBIT | -$25.64 | -$22.02 | -$18.21 | |
| Income tax expense | ||||
| Interest expense | $0.36 | $1.4 | $1.32 | $3.33 |
| Net income | ||||
| Net income | -$24.57 | -$27.03 | -$23.35 | -$21.54 |
| Income (for common shares) | -$27.03 | -$23.35 | -$21.54 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $54.85 | $47.85 | $37.72 | $46.49 |
| Selling, general & administrative | $20.8 | $20.83 | $18.93 | $10.55 |
| Total operating expenses | $75.64 | $68.67 | $56.65 | $57.04 |
| Operating income | -$75.64 | -$68.67 | -$56.65 | -$57.04 |
| Income from continuing operations | ||||
| EBIT | -$67.84 | -$67.06 | -$56.62 | -$56.42 |
| Income tax expense | ||||
| Interest expense | $3.33 | |||
| Net income | ||||
| Net income | -$71.17 | -$67.06 | -$56.62 | -$56.42 |
| Income (for common shares) | -$71.17 | -$67.06 | -$56.62 | -$56.42 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$27.03 | -$23.35 | -$21.54 | |
| Operating activities | ||||
| Depreciation | $0.33 | $0.32 | $0.34 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.16 | $1.69 | $1.67 | |
| Total cash flows from operations | -$23.66 | -$24.53 | -$18.49 | |
| Investing activities | ||||
| Capital expenditures | -$0.03 | -$0.1 | ||
| Investments | $17.82 | $10.43 | -$6.37 | |
| Total cash flows from investing | $51.56 | $17.82 | $10.39 | -$6.47 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.46 | $0.16 | $0.02 | |
| Net borrowings | $12.5 | |||
| Total cash flows from financing | $11.14 | $0.46 | $0.16 | $12.52 |
| Effect of exchange rate | $0.01 | -$0 | $0.01 | $0.13 |
| Change in cash and equivalents | -$10.01 | -$5.38 | -$13.98 | -$12.44 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$71.17 | -$67.06 | -$56.62 | -$56.42 |
| Operating activities | ||||
| Depreciation | $1.33 | $1.18 | $1.05 | $0.22 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.04 | $7.67 | $7.16 | $2.31 |
| Total cash flows from operations | -$70.67 | -$57.76 | -$48.15 | -$35.97 |
| Investing activities | ||||
| Capital expenditures | -$0.3 | -$0.41 | -$0.4 | -$0.57 |
| Investments | -$53.35 | -$4.99 | $43.19 | -$116.61 |
| Total cash flows from investing | -$53.65 | -$5.4 | $42.8 | -$117.18 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $85.97 | $68.74 | $0.61 | $116.17 |
| Net borrowings | $40 | $4.05 | ||
| Total cash flows from financing | $125.97 | $72.79 | $0.61 | $149.81 |
| Effect of exchange rate | -$0.02 | -$0.03 | ||
| Change in cash and equivalents | $1.65 | $9.62 | -$4.75 | -$3.34 |
News
Fundamentals
| Market cap | $256.72M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 64.18M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$96.49M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -2.66 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.50 |
|---|---|
| ROA | -57.02% |
| ROE | N/A |
| Debt/Equity | 0.43 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 7.68 |
| Quick ratio | N/A |